What LIB Therapeutics does

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company founded in 2015 and headquartered in Cincinnati, Ohio. The company develops and commercializes LEROCHOL (lerodalcibep-liga), a third-generation PCSK9 inhibitor approved by the FDA in December 2025 for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The product's anti-PCSK9 binding domain is an 11-kDa adnectin polypeptide fused to human serum albumin, differentiating it from monoclonal antibody-based PCSK9 inhibitors (Repatha, Praluent) and siRNA therapies (Leqvio). LEROCHOL is administered as a once-monthly subcutaneous injection with a small injection volume and extended room-temperature stability of up to three months, with sustained LDL-C reductions of approximately 50-60% demonstrated across the Phase 3 LIBerate program of over 2,900 patients.

The company operates a hybrid commercial model combining direct-to-patient cash-pay sales at $199/month through LEROCHOL.com with traditional healthcare-provider prescription distribution. Geographic expansion is advancing through an EMA Marketing Authorization Application with anticipated 2H 2026 approval, a Greater China Biologics License Application expected 1H 2026 via an exclusive partnership with Everest Medicines (succeeding the original $325M Hasten Biopharmaceutical collaboration), and pursuit of additional EU regional partners. The company is led by a credentialed team including CEO David Cory (former Eiger BioPharmaceuticals CEO, co-founder of CoTherix) and Founder/Chief Executive & Scientific Officer Dr. Evan Stein, supported by senior commercial and operational leadership hired in 2024-2026 to scale the US launch and ex-US regulatory strategy.

Name

LIB Therapeutics

Legal name

LIB Therapeutics, Inc.

Website

https://libtherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company that develops LEROCHOL, a once-monthly third-generation PCSK9 inhibitor FDA-approved in December 2025 for reducing LDL cholesterol in adults with hypercholesterolemia, marketed direct-to-patient at $199/month.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preventive Cardiology & Lipidology (HLAKABAF)

akta.pro secondary industry

Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)

Keywords

• PCSK9 inhibitors
• Lipid lowering therapy
• Cardiovascular therapeutics
• LDL cholesterol treatment
• Biopharmaceutical products

Headquarters

HQ city

Cincinnati

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Direct-to-patient cash-pay sales of LEROCHOL at $199/month with prefilled syringe and auto-injector formulations. Revenue also generated through payer reimbursement and insurance coverage for prescriptions written by healthcare providers.
2. Licensing Royalties (Greater China): Everest Medicines holds exclusive license to develop, register and commercialize LEROCHOL in Greater China. LIB Therapeutics receives licensing revenue and royalties from this territory under the $325M strategic collaboration with Hasten Biopharmaceutical.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

LIB Therapeutics develops and commercializes LEROCHOL (lerodalcibep-liga), a third-generation PCSK9 inhibitor administered as a once-monthly, small-volume subcutaneous injection for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The product uses a proprietary adnectin-based protein-binding technology with extended room-temperature stability and is sold via a direct-to-patient cash-pay model at $199/month alongside traditional prescription-based distribution.

Product overview

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company with a single focused product: LEROCHOL (lerodalcibep-liga). LEROCHOL is a third-generation PCSK9 inhibitor approved by the FDA in December 2025 for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is administered as a once-monthly subcutaneous injection with extended room-temperature stability. The company is pursuing additional regulatory approvals in Europe (EMA MAA submitted) and Greater China (BLA expected 1H 2026).

Differentiator

Problem solved

Functional benefit

Brands

• LEROCHOL: Brand name for the company's FDA-approved drug lerodalcibep-liga, a third-generation PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia.

Products and services

• LEROCHOL (lerodalcibep-liga) Pre-filled Syringe A third-generation PCSK9 inhibitor administered as a once-monthly, single small-volume subcutaneous injection for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Available via direct-to-patient cash-pay subscription at $199/month through LEROCHOL.com and via traditional prescription with payer reimbursement.
• LEROCHOL (lerodalcibep-liga) Auto-Injector Pen Auto-injector pen formulation of LEROCHOL for patient self-administration of once-monthly subcutaneous PCSK9 inhibitor therapy. Expected to launch later in 2026.

Quantifiable outcome

• 52% mean LDL-C reduction through 124 weeks (2.3 mmol/L absolute reduction)
• +8 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Everest MedicinescoreChannel Partner/ Reseller/ Distributor · 1 December 2025Everest Medicines (HKEX 1952.HK) holds exclusive license to develop, register and commercialize LEROCHOL in Greater China. Everest entered into strategic agreement with Hasten Biopharmaceutical and LIB Therapeutics in December 2025. Everest focuses on discovering, developing, manufacturing and commercializing transformative pharmaceutical products for Asian markets.
• Hasten Biopharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 12 September 2023$325 million strategic collaboration announced September 12, 2023 to develop and commercialize lerodalcibep in Greater China. Hasten obtained rights to develop and commercialize lerodalcibep and is responsible for regulatory approval in these territories. Everest Medicines subsequently entered into strategic agreement with Hasten in December 2025 to license LEROCHOL in Greater China.

Scale indicators9 records

Recent moves6 records

Direct peers

• Novartis (Leqvio/inclisiran): Novartis acquired The Medicines Company to commercialize Leqvio (inclisiran), a siRNA PCSK9-targeted therapy administered twice yearly. Leqvio is the most differentiated direct competitor offering an alternative mechanism and longer dosing interval compared to lerodalcibep.
• Esperion Therapeutics (Nexletol/Nexlizet): Esperion markets bempedoic acid for LDL-C lowering in statin-intolerant patients. While targeting a different mechanism, Esperion competes in the same prescriber workflow as adjunct lipid-lowering therapy for ASCVD patients who fail to achieve LDL-C goals on statins.
• Amgen (Repatha/evolocumab): Amgen markets Repatha, the first FDA-approved PCSK9 monoclonal antibody inhibitor for LDL-C reduction. Repatha is the direct head-to-head competitor to LEROCHOL in the same indication (hypercholesterolemia, HeFH, ASCVD), creating the central competitive dynamic LIB Therapeutics must navigate.
• Regeneron / Sanofi (Praluent/alirocumab): Regeneron and Sanofi jointly commercialize Praluent, the second approved monoclonal antibody PCSK9 inhibitor in the same market segment. Praluent competes directly on efficacy, dosing, and formulary positioning for hypercholesterolemia and ASCVD patients.

Others

• Ionis Pharmaceuticals: Ionis Pharmaceuticals originated the antisense and siRNA chemistries behind Leqvio's PCSK9 mechanism and continues to develop lipid-targeting nucleic acid therapies. Ionis is comparable as a developer of PCSK9/LDL-C targeted therapeutics with similar lipid biology expertise.

Emerging players

• Verve Therapeutics: Verve Therapeutics is developing in vivo gene-editing therapies targeting PCSK9 for one-and-done LDL-C reduction. Its PCSK9 gene-editing approach targets the same biological pathway as LEROCHOL and represents a potential future disruptive therapy.
• NewAmsterdam Pharma (obicetrapib): NewAmsterdam Pharma is developing obicetrapib, a next-generation CETP inhibitor for LDL-C lowering. It is in late-stage Phase 3 trials and would enter the same adjunct-to-statin market space that LEROCHOL targets for ASCVD and FH patients.

Regional players

• Madrigal Pharmaceuticals: Madrigal commercializes Rezdiffra for MASH (liver disease) but operates in the cardiometabolic space and competes for cardiovascular-metabolic prescriber attention. Comparable as a recently-launched specialty cardiometabolic drug company with a single approved product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/libtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LIB Therapeutics